IL-PRICEFX
Pricefx , the global leader in cloud pricing software, today announced another year of tremendous growth during its fiscal year ending December, 31, 2019. The company has grown by 85% on average each year for the last four years – 3 to 4 times the industry standard for pricing companies. As a result, Pricefx is continuing to expand its market share, particularly in the U.S. where the company more than doubled its total revenue.
Market Demand and Customer Wins
Gartner Inc. included Pricefx in the Magic Quadrant for Configure, Price and Quote Application Suites , as well as the Hype Cycle for CRM Sales Technology, 2019 as a Sample Vendor of Price Optimization and Management for B2B. The latter report states, “price optimization and management is close to the Plateau of Productivity because it is able to demonstrate quantifiable and tangible improvements in margin and revenue in successful implementations.”
Additionally, Gartner’s Market Guide for B2B Price Optimization and Management Software for 2019 includes Pricefx and states that it expects “the PO&M market to continue to grow rapidly during the next three years” and that “PO&M software has a rapid payback on investment (often less than six months).”
Pricefx currently has more than 100 customers across 37 countries, which include some of the largest manufacturing, retailing and energy businesses in the world. In 2019, Pricefx signed nearly 20 new enterprise customers with revenue in excess of $2 billion. New customers include Lyreco, Phillips 66, Scotts-Miracle Gro and Watsco.
Company Expansion
To scale for the rising demand of its easy-to-use pricing solutions, Pricefx also expanded its footprint in North America. The company more than doubled its headcount, adding 140 new employees in 2019.
In November 2019, Pricefx closed its Series B financing round with a total of €48 million in its coffers, which will be used to fuel the company’s continued market expansion and product development. On the heels of this latest funding, the company’s valuation has nearly tripled in the last twelve months.
Product Accolades and Advancements
Last year, Pricefx became the first solution provider to achieve Gold-Level Status for SAP® PartnerEdge® Build. The company also secured the highest rating on G2 Crowd for enterprise-grade pricing software. Pricefx won Product of the Year in the 2019 Sales and Marketing Technology awards (SAMMYs), the only pricing solution to do so, and was named the Gold winner in Enterprise Product of the Year - Sales Software.
The 2019 SaaS Awards program named Pricefx a finalist in the category “Best SaaS Product for Sales / Marketing” and the company was named a Bronze winner for Cloud Computing/SaaS Product or Service for Sales by the Customer Sales & Service World Awards .
Pricefx also completed its evolution to an enterprise-grade platform , announcing that subscribers of the company’s core SaaS product offerings receive full access to the entire platform feature set for no additional cost. By including the platform with core product subscriptions, Pricefx further lowered the total cost of ownership for its customers.
The fall product release brought forth Unity UI , a sleek, modern, intuitive user interface. Unity represented the first major UI update for Pricefx since its initial launch and dramatically improved the ease of use, consistency and responsiveness of Pricefx to create a better user experience on multiple devices. Last spring, Pricefx announced plug-and-play integrations between its CPQ software and the industry’s leading enterprise-grade customer relationship management (CRM) solutions, including Salesforce, Microsoft Dynamics 365 and SAP Cloud for Customer.
“In 2019, Pricefx continued to deliver a fast, flexible and friendly pricing solution to enterprises looking to increase revenue and profits,” said Patrick Adams, chief revenue officer of Pricefx. “Investor support, industry accolades, customer wins and new product innovation point to strong demand for Pricefx’s true cloud-native pricing platform. We are excited about 2019’s results and expect to continue our amazing growth into 2020 with expanded adoption of the platform and new solutions designed to give our customers a competitive edge.”
In Q1 2020, Pricefx Advantage, the company’s new partner program, will officially launch. The program seeks to create a connected ecosystem of pricing strategists, system integrators and Independent Software Vendors (ISV’s) who will team with Pricefx to help customers achieve pricing superiority at scale, faster than anyone else in the market.
Follow Pricefx
Blog: https://www.pricefx.com/site/blog/
Twitter: https://twitter.com/price_fx
LinkedIn: https://www.linkedin.com/company/price-f-x-/
About Pricefx
Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Their innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to more than 100 customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .
Gartner Disclaimer: Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner’s research organization and should not be construed as statements of fact. Gartner disclaims all warranties, express or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200130005160/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 13:00:00 CET | Press release
Summit debuts Mayors in Motion initiative and CoMotion Urban Visionary Distinction as Riyadh showcases its rise as global mobility testbed Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom